Sanggenol L exhibits significant anti-inflammatory and antioxidant properties, making it a promising candidate for therapeutic applications in chronic inflammatory diseases. It has been studied for its ability to inhibit key pro-inflammatory mediators such as nitric oxide and prostaglandin E2 by suppressing the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). This suggests potential use in conditions like arthritis, neurodegenerative disorders, and other inflammation-driven pathologies.

Additionally, Sanggenol L demonstrates hepatoprotective effects, helping to shield liver cells from damage caused by oxidative stress and toxins. Its antioxidant activity enhances cellular defense mechanisms by upregulating enzymes like superoxide dismutase and catalase. These properties support its investigation in liver-related therapeutics, including fatty liver disease and drug-induced liver injury.

Emerging research also highlights its anticancer potential. Sanggenol L has shown the ability to induce apoptosis and inhibit proliferation in certain cancer cell lines, particularly in liver and colon cancers. It modulates signaling pathways such as PI3K/Akt and MAPK, which are involved in cell survival and growth, indicating a role in chemopreventive or adjuvant cancer therapies.

Due to its natural origin and multi-target biological activities, Sanggenol L is being explored as a lead compound for developing nutraceuticals and functional ingredients in health supplements aimed at promoting longevity and preventing age-related diseases.